Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
19
RADLY Quote, Financials, Valuation and Earnings
Last price:
$2.44
Seasonality move
:
4%
Day range:
$2.40 - $2.44
52-week range:
$2.21 - $14.00
Dividend yield:
2.5%
P/E ratio:
21.92x
P/S ratio:
0.57x
P/B ratio:
3.71x
Volume:
1.9K
Avg. volume:
2.4K
1-year change:
-49.05%
Market cap:
$4.2B
Revenue:
$7.2B
EPS (TTM):
$0.11
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Raia Drogasil SA has -- downside to fair value with a price target of -- per share.
RADLY vs. S&P 500
-
Over the past 5 trading days, Raia Drogasil SA has overperformed the S&P 500 by 3.52% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Raia Drogasil SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Raia Drogasil SA revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Raia Drogasil SA reported revenues of $1.7B.
Earnings Growth
-
Raia Drogasil SA earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Raia Drogasil SA reported earnings per share of $0.02.
Enterprise value:
4.7B
EV / Invested capital:
--
Price / LTM sales:
0.57x
EV / EBIT:
12.17x
EV / Revenue:
0.66x
PEG ratio (5yr expected):
16.77x
EV / Free cash flow:
67.57x
Price / Operating cash flow:
59.18x
Enterprise value / EBITDA:
7.25x
Gross Profit (TTM):
$2.1B
Return On Assets:
5.42%
Net Income Margin (TTM):
2.97%
Return On Equity:
18.54%
Return On Invested Capital:
12.31%
Operating Margin:
4.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $5.9B | $7.1B | $7.1B | $1.8B | $1.7B | |
| Gross Profit | $1.8B | $2.1B | $2.1B | $537.1M | $491.8M | |
| Operating Income | $394.3M | $415M | $417.2M | $106.3M | $82.8M | |
| EBITDA | $596.4M | $685.8M | $641.6M | $190.4M | $156.1M | |
| Diluted EPS | $0.12 | $0.13 | $0.11 | $0.02 | $0.02 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $1.8B | $2.1B | $2.4B | $2.3B | |
| Total Assets | $2.5B | $3.3B | $3.6B | $4.1B | $3.9B | |
| Current Liabilities | $824.9M | $1.2B | $1.5B | $1.7B | $1.7B | |
| Total Liabilities | $1.7B | $2.3B | $2.5B | $2.9B | $2.8B | |
| Total Equity | $777M | $1B | $1.1B | $1.2B | $1.1B | |
| Total Debt | $282.7M | $454.5M | $446.7M | $566M | $550.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $271.5M | $246.6M | $313.1M | $132.3M | $88.9M | |
| Cash From Investing | -$248M | -$255.9M | -$277.8M | -$40.3M | -$54.7M | |
| Cash From Financing | -$41.5M | $17M | -$34.9M | -$92M | -$55.3M | |
| Free Cash Flow | $30.6M | -$9.6M | $68.8M | $91.2M | $42.8M | |
RADLY
Sector
Market Cap
$4.2B
--
Price % of 52-Week High
17.43%
--
Dividend Yield
2.5%
--
Shareholder Yield
--
--
1-Year Price Total Return
-49.05%
--
Beta (5-Year)
0.163
--
Dividend yield:
2.5%
Annualized payout:
$0.06
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.45
200-day SMA
Sell
Level
$3.61
Bollinger Bands (100)
Sell
Level
2.61 - 3.45
Chaikin Money Flow
Buy
Level
355
20-day SMA
Sell
Level
$2.69
Relative Strength Index (RSI14)
Sell
Level
44.75
ADX Line
Buy
Level
2.98
Williams %R
Buy
Level
-84.9462
50-day SMA
Sell
Level
$2.72
MACD (12, 26)
Buy
Level
0.59
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
2.3K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (-0.1903)
Buy
Beneish M-Score
(Annual)
Level (-2.938)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.7573)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Raia Drogasil SA is a large retail drug store operator in Brazil. The company is engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. Its brands include Impulso, Amplimed, HealthBit, Stix, 4Bio, Drogasil, Raia and others.
Stock Forecast FAQ
In the current month, RADLY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RADLY average analyst price target in the past 3 months is --.
-
Where Will Raia Drogasil SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Raia Drogasil SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Raia Drogasil SA?
Analysts are divided on their view about Raia Drogasil SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Raia Drogasil SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Raia Drogasil SA's Price Target?
The price target for Raia Drogasil SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RADLY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Raia Drogasil SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RADLY?
You can purchase shares of Raia Drogasil SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Raia Drogasil SA shares.
-
What Is The Raia Drogasil SA Share Price Today?
Raia Drogasil SA was last trading at $2.44 per share. This represents the most recent stock quote for Raia Drogasil SA. Yesterday, Raia Drogasil SA closed at $2.44 per share.
-
How To Buy Raia Drogasil SA Stock Online?
In order to purchase Raia Drogasil SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
